Irinotecan Mylan Generics (Irinotecan Hydrochloride Trihydrate)

After infusion, irinotecan is metabolised by liver enzymes into the active metabolite SN‑38. SN‑38 binds to DNA‑topoisomerase I, stabilising the enzyme‑DNA complex and preventing the re‑ligation of single‑strand DNA breaks. This blocks DNA replication and transcription, causing accumulation of DNA damage that leads to cancer cell death.

The dose of Irinotecan is individualized by the prescribing oncologist based on factors such as cancer type, treatment regimen, patient weight, renal and hepatic function, and prior therapy. Specific dosing schedules are not provided here; clinicians determine the appropriate amount and frequency for each patient.

Irinotecan is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy, and breastfeeding is contraindicated because the drug can be excreted in milk and may harm the infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as oxaliplatin (a platinum compound) or 5‑fluorouracil (a pyrimidine analogue). Its unique mechanism targets DNA‑topoisomerase I, offering efficacy in tumors resistant to other drugs, but it also has a distinct toxicity profile, notably delayed diarrhea and neutropenia.

Irinotecan injection solution must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the product. Before administration, allow the solution to reach room temperature if required by the preparation protocol.

Irinotecan is given as an intravenous infusion, usually over 30 to 90 minutes depending on the specific regimen. The infusion is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring for infusion‑related reactions and supportive care measures such as anti‑emetics and antidiarrheals.

The most serious adverse events include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea that can cause dehydration and electrolyte imbalance, and rare but severe allergic reactions such as anaphylaxis. Prompt recognition and medical intervention are essential to mitigate these risks.

Irinotecan should be avoided in patients with known hypersensitivity to the drug or its components, those with severe hepatic impairment, and individuals who are pregnant. Patients with a homozygous UGT1A1*28 genotype may also be at high risk for toxicity and should be evaluated carefully before treatment.